After the markets closed on Tuesday, April 22, Gilead reported strong first-quarter operating results behind robust Sovaldi sales of $2.3 billion—over two times the consensus expectation; exhibit 1, on page 2, provides a complete variance analysis of the company’s results versus our expectations. Sovaldi sales for the first quarter wereRead More
Post Tagged with: "GILD"
Gilead Sciences Says FDA Accepts New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy
Gilead Sciences (GILD) says the FDA accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor forRead More
Biotech stocks (SPSIBI) are higher Monday following a Barron’s article suggesting selected shares look attractive following a 27% selloff in the sector from February highs of near $4,400. Mentioned in the article are Amgen (AMGN), up 2.1% at $114.29 per share, Gilead Sciences (GILD) up 1.6% at $67.09, and CelgeneRead More